Synthesis reveals indium(III) complexes exhibit significant activity and selectivity against K. pneumoniae, suggesting a potential treatment option.
A series of dimethyl indium(III) 8-hydroxyquinolinates; [InMe2(Q")] (1), [InMe2(Q'Cl)] (2), [InMe2(QCl2)] (3), [InMe2(QBr2)] (4), [InMe2(QI2)] (5), [InMe2(QICl)] (6), and a series of indium(III) tris(8-hydroxyquinolinates); [In(Q")3]•H2O (7), [In(QCl2)3] (8), [In(QBr2)3] (9), [In(QI2)3] (10), and [In(QICl)3] (11), (where Q"-H = C9H7NO; Q'Cl-H = C9H6NOCl, QCl2-H = C9H5NOCl2; QBr2-H = C9H5NOBr2; QI2-H = C9H5NOI2; and QICl-H = C9H5NOICl) were synthesised, characterised, and evaluated for their antibacterial activity against Gram-positive bacteria (vancomycin-resistant E. faecalis, S. aureus, methicillin-resistant S. aureus), Gram-negative bacteria (K. pneumoniae, A. baumannii, P. aeruginosa, and E. coli) and mammalian cell inhibition of L929 fibroblasts. Single crystal X-ray diffraction data of 2-4 indicates the dimethylindium complexes are dimeric in the solid-state through 'In2O2' bridging. Complexes 1-6 exhibit significant activity and selectivity against three multi-drug resistant strains of K. pneumoniae, with MIC (minimum inhibitory concentration) values as low as 49 nM and selectivity indices as high as 159 against carbapenem-resistant strain RH201207. The antibacterial activity and selectivity against K. pneumoniae is generally enhanced upon complexation of the 8-hydroxyquinolinate ligands to indium(III).
No takes yet. Share an insight, caveat, or question.
Soukup et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: